These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 36155521)
1. A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer's Disease. Xu C; Zhao L; Dong C J Alzheimers Dis; 2022; 90(2):495-512. PubMed ID: 36155521 [TBL] [Abstract][Full Text] [Related]
2. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Hansson O; Lehmann S; Otto M; Zetterberg H; Lewczuk P Alzheimers Res Ther; 2019 Apr; 11(1):34. PubMed ID: 31010420 [TBL] [Abstract][Full Text] [Related]
3. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652 [TBL] [Abstract][Full Text] [Related]
4. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
5. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Shoji M Front Biosci; 2002 Apr; 7():d997-1006. PubMed ID: 11897565 [TBL] [Abstract][Full Text] [Related]
8. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Andreasen N; Blennow K Peptides; 2002 Jul; 23(7):1205-14. PubMed ID: 12128078 [TBL] [Abstract][Full Text] [Related]
9. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267 [TBL] [Abstract][Full Text] [Related]
10. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. Hirtz C; Busto GU; Bennys K; Kindermans J; Navucet S; Tiers L; Lista S; Vialaret J; Gutierrez LA; Dauvilliers Y; Berr C; Lehmann S; Gabelle A Alzheimers Res Ther; 2023 Feb; 15(1):34. PubMed ID: 36800984 [TBL] [Abstract][Full Text] [Related]